Eris Lifesciences forms JV with MJ Biopharm to enter insulin segment

04 Dec 2021 Evaluate

Eris Lifesciences has formed a joint venture with Mumbai-based MJ Biopharm to enter the insulin segment. Eris MJ Biopharm, the 70:30 joint venture (with Eris holding a 70 per cent stake), would primarily engage in marketing and distribution of human and analogue insulin including Aspart, Glargine and Lispro and GLP-1 agonists and potentially other biopharma products in India. MJ will be responsible for the development, manufacturing and supply of these products to the JV.

Eris Lifesciences is the only publicly listed Indian pharmaceutical company with a pure-play domestic branded formulations business model.

Eris Lifesciences Share Price

1402.65 12.95 (0.93%)
19-Dec-2024 14:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1814.50
Dr. Reddys Lab 1327.25
Cipla 1507.70
Lupin 2154.10
Zydus Lifesciences 984.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.